Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.

Frontiers in immunology - 1 Jan 2021

Thakur Archana, Scholler John, Kubicka Ewa, Bliemeister Edwin T, Schalk Dana L, June Carl H, Lum Lawrence G

Abstract excerpt

Adoptive T cell therapies for solid tumors is challenging. We generated metabolically enhanced co-activated-T cells by transducing intracellular co-stimulatory (41BB, ICOS or ICOS-27) and CD3ζ T cell receptor signaling domains followed by arming with bispecific antibodies (BiAbs) to produce armed "Headless CAR T cells" (hCART). Various hCART armed with BiAb directed at CD3ϵ and various tumor associated antigens...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Coculture Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Immunotherapy, Adoptive

Share to MCF-7 Cells

Share to Receptor, ErbB-2

Share to Receptors, Chimeric Antigen

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34290709
DOI: 10.3389/fimmu.2021.690437
PMCID: PMC8288104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.PMID 34290709Read ↗

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapySemantic proximity Read ↗

AI-Guided CAR Designs and AKT3 Degradation Synergize to Enhance Bispecific and Trispecific CAR-T Cell Persistence and Overcome Antigen EscapeSemantic proximity Read ↗

CAR-T-drug conjugate against solid tumorSemantic proximity Read ↗

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read ↗

Bispecific antibodies for immune cell retargeting against cancerSemantic proximity Read ↗

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.Semantic proximity Read ↗

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapySemantic proximity Read ↗

Novel Approaches to Enhance the Specificity and Safety of Engineered T CellsSemantic proximity Read ↗

Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastomaSemantic proximity Read ↗

Development of T-cell engagers selective for cells co-expressing two antigensSemantic proximity Read ↗

Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor responseSemantic proximity Read ↗

Engineering One-Signal Activated TILs with CD3ζ-CD28 Chimeras Optimizes the Antitumor Efficacy of TIL-Based ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.